Kevin J. Harrington

Brigham and Women's Hospital — United States

Medicine · Health Sciences

114h-index71.6kcitations1.5kworks5.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Head and Neck Cancer Studies(387), Virus-based gene therapy research(325), Cancer Immunotherapy and Biomarkers(200), CAR-T cell therapy research(195), Cancer Research and Treatments(165)

Publications1.5k total

Figure 4 from Xevinapant plus Chemoradiotherapy Negatively Sculpts the Tumor-Immune Microenvironment in Head and Neck Cancer
2025Open Access
Figure S4 from Xevinapant plus Chemoradiotherapy Negatively Sculpts the Tumor-Immune Microenvironment in Head and Neck Cancer
2025Open Access
Figure S6 from Xevinapant plus Chemoradiotherapy Negatively Sculpts the Tumor-Immune Microenvironment in Head and Neck Cancer
2025Open Access
Figure S7 from Xevinapant plus Chemoradiotherapy Negatively Sculpts the Tumor-Immune Microenvironment in Head and Neck Cancer
2025Open Access
Figure S5 from Xevinapant plus Chemoradiotherapy Negatively Sculpts the Tumor-Immune Microenvironment in Head and Neck Cancer
2025Open Access
Figure 3 from Xevinapant plus Chemoradiotherapy Negatively Sculpts the Tumor-Immune Microenvironment in Head and Neck Cancer
2025Open Access
Figure S1 from Xevinapant plus Chemoradiotherapy Negatively Sculpts the Tumor-Immune Microenvironment in Head and Neck Cancer
2025Open Access
Data from Xevinapant plus Chemoradiotherapy Negatively Sculpts the Tumor-Immune Microenvironment in Head and Neck Cancer
2025Open Access
Figure 2 from Xevinapant plus Chemoradiotherapy Negatively Sculpts the Tumor-Immune Microenvironment in Head and Neck Cancer
2025Open Access
Figure S3 from Xevinapant plus Chemoradiotherapy Negatively Sculpts the Tumor-Immune Microenvironment in Head and Neck Cancer
2025Open Access
Figure 1 from Xevinapant plus Chemoradiotherapy Negatively Sculpts the Tumor-Immune Microenvironment in Head and Neck Cancer
2025Open Access
Figure S2 from Xevinapant plus Chemoradiotherapy Negatively Sculpts the Tumor-Immune Microenvironment in Head and Neck Cancer
2025Open Access
Supplementary Data from Xevinapant plus Chemoradiotherapy Negatively Sculpts the Tumor-Immune Microenvironment in Head and Neck Cancer
2025Open Access
Subcutaneous amivantamab in recurrent/metastatic head and neck squamous cell cancer after disease progression on checkpoint inhibitor and chemotherapy: Preliminary results from the phase 1b/2 OrigAMI-4 study
Oral Oncology·2025· 1 citedOpen Access
Developing a therapeutic elastase that stimulates anti-tumor immunity by selectively killing cancer cells
Cell Reports Medicine·2025Open Access
Second-event endpoints (EFS2, PRFS2 and PFS2) after anti-PD-(L)1-based RCTs: a systematic review and meta-analysis
Journal for ImmunoTherapy of Cancer·2025Open Access
Multicellular Calcium Waves in Cancer-Associated Fibroblasts Regulate Neuronal Mimicry and Anisotropy Leading to Immune Exclusion
2025Open Access
Xevinapant plus Chemoradiotherapy Negatively Sculpts the Tumor-Immune Microenvironment in Head and Neck Cancer
Cancer Research Communications·2025Open Access
Neoadjuvant and Adjuvant Pembrolizumab (Pembro) Plus Standard of Care (SOC) in Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC): Postoperative Risk Subgroup Analysis of KEYNOTE-689
International Journal of Radiation Oncology*Biology*Physics·2025Open Access
Rapid expansion of podoplanin-positive fibroblasts following radiation limits the anti-tumour CD8+ T-cell response to radiotherapy
2025Open Access
page 1 of 73Next →

Frequent Co-authors

Alan Melcher(13), Hardev Pandha(10), Richard G. Vile(9), Lisa Licitra(8), Christopher M. Nutting(7), Makoto Tahara(6), Fiona Errington‐Mais(6), Peter J. Selby(6), Robert L. Ferris(5), Robert I. Haddad(5), Barbara Burtness(5), Ezra E.W. Cohen(5), Mererid Evans(5), Robin Prestwich(5), Jérôme Fayette(4), Caroline Even(4), Francis P. Worden(4), Nabil F. Saba(4), Tamara Rordorf(4), Maura L. Gillison(4)